Diabetes Mellitus, Type 2  >>  Synjardy (empagliflozin/metformin)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Synjardy (empagliflozin/metformin) / Boehringer Ingelheim, Eli Lilly
NCT00789035 / 2008-000640-14: 12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients

Checkmark
Apr 2013 - Apr 2013: 
Completed
2b
408
Europe, RoW
BI 10773, placebo, metformin
Boehringer Ingelheim
Diabetes Mellitus, Type 2
10/09
 
NCT00749190 / 2008-000641-54: BI 10773 add-on to Metformin in Patients With Type 2 Diabetes

Checkmark
Aug 2013 - Aug 2013: 
Checkmark
Apr 2013 - Apr 2013: 
Completed
2
495
US, Europe, RoW
BI 10773, placebo, sitagliptin
Boehringer Ingelheim
Diabetes Mellitus, Type 2
10/09
 
NCT00881530 / 2008-007938-21: Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension

Checkmark
Nov 2013 - Nov 2013: 
Checkmark AACE 2013 (LBA)
May 2013 - May 2013: AACE 2013 (LBA)
Checkmark Data
More
Completed
2
660
US, Europe, RoW
BI 10773, Metformin, Sitagliptin
Boehringer Ingelheim
Diabetes Mellitus, Type 2
05/11
 

Download Options